Sysmex Corporation (6869.T)

8.109,00 +31,00 (+0,38%) Al 09:44AM JST. Mercato aperto.

Sysmex Corporation

1-5-1 Wakinohama-kaigandori
Chuo-ku
Kobe 651-0073
Japan
81 78 265 0500
https://www.sysmex.co.jp

Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 9.500

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Hisashi Ietsugu	Chairman of the Managing Board & Group CEO	229M	N/D	1949
Mr. Kaoru Asano	President & Representative Director	N/D	N/D	1958
Mr. Chris Cappella	Chief Financial Officer	N/D	N/D	N/D
Mr. Tomokazu Yoshida	Managing Executive Officer, CTO & Member of the Managing Board	N/D	N/D	1964
Mr. Frank Buescher	Senior Executive Officer	N/D	N/D	N/D
Mr. Iwane Matsui	Senior Managing Executive Officer & Member of the Managing Board	N/D	N/D	1961
Mr. Kenji Tachibana	Sr. MD of Corp Mgmt & Regulatory Affairs, Sr. Exec. Officer & Member of the Managing Board	N/D	N/D	1957
Mr. Mamoru Kubota	Senior Executive Officer	N/D	N/D	N/D
Mr. Kensuke Iizuka	Senior Executive Officer & Executive VP of Corporate Business Planning Div.	N/D	N/D	N/D
Mr. Zuo Hui Peng	Executive Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in JPY.

Descrizione

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Governance aziendale

L'ISS Governance QualityScore di Sysmex Corporation al 1 dicembre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 4; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.